Janus kinase (JAK) inhibitors have emerged as a novel orally administered small molecule therapy for the treatment of ulcerative colitis and possibly Crohn’s disease. These molecules are designed to selectively target the activity of specific JAKs and offer a targeted mechanism of action without risk of immunogenicity. Based on data from clinical trials in rheumatoid arthritis and phase 2 studies in inflammatory bowel disease, tofacitinib and other JAK inhibitors are likely to become a new form of medical therapy for the treatment of inflammatory bowel disease.
All Keywords
【저자키워드】 Inflammatory bowel disease, ulcerative colitis, Tofacitinib, Janus kinase inhibitors, Crohn’s disease, Small molecule therapy,
【저자키워드】 Inflammatory bowel disease, ulcerative colitis, Tofacitinib, Janus kinase inhibitors, Crohn’s disease, Small molecule therapy,